Enhertu

Enhertu (trastuzumab deruxtecan) is an advanced intravenous medication used for targeted cancer therapy. It combines a monoclonal antibody with a cytotoxic agent to deliver treatment directly to cancer cells.

Enhertu is primarily used in the treatment of certain types of cancer, particularly those that overexpress the HER2 protein. This medication is designed to target and destroy cancer cells while minimizing damage to healthy tissues. Patients and healthcare providers often explore 'what is Enhertu used for' to understand its role in advanced cancer therapies.

Common effects of Enhertu may include fatigue, nausea, and hair loss. Some patients may experience more severe side effects, such as decreased blood cell counts or damage to the lungs. It is important to monitor these effects closely under medical supervision.

Enhertu should be handled with care, as it is intended for intravenous use only. Patients should be aware of potential allergic reactions and inform their healthcare provider of any pre-existing conditions. Proper storage and administration protocols must be followed to ensure safety.

Enhertu may interact with other medications, particularly those that affect the immune system or blood cell production. Patients should avoid alcohol and consult their healthcare provider before taking any new medications. CYP inhibitors and other drugs that affect liver enzymes may also influence its effectiveness.